Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 46,003

Document Document Title
WO/2014/099696
The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatme...  
WO/2014/094664
The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparin...  
WO/2014/100438
The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhib...  
WO/2014/100540
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  
WO/2014/100833
Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.  
WO/2014/100359
Provided herein are 8'-Hydroxy-2-CF3-dihydroergotamine (8 ' OH-2-CF3 -DHE) compounds, compositions, and dosage forms containing such compositions. Also provided herein are methods of treatment, prevention, or amelioration of a variety of...  
WO/2014/094632
A pharmaceutical composition for treating headache, prepared from eleven Chinese herbal medicines: Chinese angelica root, ligusticum chuanxiong, radix paeoniae lactiflorae, prepared rhizome of rehmannia, uncaria tomentosa, leatherleaf mi...  
WO/2014/096212
The present invention is concerned with novel tricyclic 3,4-dihydro-2H-pyrido[l,2-a]pyrazine-l,6-dione derivatives of Formula (I) wherein R1, R2, R3, R4, L, Y, Z and X have the meaning defined in the claims. The compounds according to th...  
WO/2014/096377
New hydroxy aliphatic substituted phenyl aminoalkyi ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or m...  
WO/2014/096941
The present disclosure provides cyclic sulfonamides of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, and n are defined as set forth in the specification. The present disclosure is ...  
WO/2014/090515
The present invention relates to an algal extract comprising sulphated and non-sulphated polyanionic polysaccharides, to a method for preparing an algal extract, and also to the therapeutic and prophylactic uses thereof.  
WO/2014/089913
The present invention relates to a compound shown in a formula (I), a method for preparing the compound, a pharmaceutical composition containing the compound, and applications of the compound in preparing drugs for preventing and/or trea...  
WO/2014/090990
The invention relates to a pharmaceutical composition comprising a leukotriene antagonist or a leukotriene receptor antagonist for the treatment of a subject suffering from dementia in Parkinson's disease. Further, the invention provides...  
WO/2014/092006
[Problem] To provide a novel compound that exhibits an agonistic effect on dopamine D2 receptors. [Solution] A compound that can be represented by general formula (I) (in which R1 represents a C1-6 alkyl or the like; R2 represents hydrog...  
WO/2014/092104
The invention provides compounds represented by formula (1) (in the formula, Het represents the formula (Het-1) or the like; A represents the formula (A-1) or the like; B represents (B-1) or the like; R1A represents a hydrogen atom, alky...  
WO/2014/090929
Pharmaceutical compositions comprising vortioxetine and donepezil are provided and the use of such composition for the treatment of cognitive dysfunctions.  
WO/2014/093791
Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use...  
WO/2014/092175
The present invention addresses the problem of providing a method for manufacturing a comparatively high-purity ≥4-mer polyphenol by precisely isolating said ≥4-mer polyphenol from a polyphenol mixture. This method for manufacturing ...  
WO/2014/091876
The fluorine-substituted piperidine compound represented in formula (I) or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of disorders that are on the basis of orexin (OX) receptor antagonism includin...  
WO/2014/093114
The present invention relates to PPARy- sparing compounds and pharmaceutical compositions formulated with such compounds that are useful for treating, delaying the onset of, or reducing the symptoms of a neurodegenerative disorder includ...  
WO/2014/091415
The invention relates to indole carboxamide derivatives of formula (I), (I) wherein R1, R 2, R 3, R 4, R5 and R6 are as defined in the description, their preparation and their use as pharmaceutically active compounds.  
WO/2014/092227
The present invention relates to a composition for treatment of diseases related to the removal of extracellular alpha-synuclein and to a method for screening a therapeutic agent for said diseases.  
WO/2014/090921
The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system com...  
WO/2014/091352
The present invention provides compounds of Formula (I), and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure (I) wherein the variables R1, R2, R3, ...  
WO/2014/093901
Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.  
WO/2014/093871
The present invention relates to methods for treating pruritus with anti-pruritic compositions.  
WO/2014/092100
The purpose of the invention is to provide a compound or salt thereof that is useful as an agent for the prevention or treatment of epilepsy, neurodegenerative disease, and the like. The invention pertains to compounds represented by for...  
WO/2014/093918
The disclosure provides compositions, methods and kits for treatment of neuronal injury. In one embodiment, the composition comprises polyethylene glycol (PEG), and magnesium in one composition. In another embodiment, the composition com...  
WO/2014/093475
Provided herein are methods and compositions for treatment of patients with Parkinson's disease and, in particular, motor impairments in patients with Parkinson's disease, using an aminopyridine.  
WO/2014/089620
The present invention provides compositions comprising a combination of: (i) one or more B vitamins or alternative form(s), derivative(s), or salt(s) thereof, or combinations thereof, and/or source(s) thereof; and (ii) phosphatidylserine...  
WO/2014/093190
In its many embodiments, the present invention provides certain C2-ring-substituted iminothiadiazine compounds, or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers. The novel compounds of th...  
WO/2014/093277
The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or ...  
WO/2014/091020
The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spin...  
WO/2014/093251
Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride chann...  
WO/2014/086098
Disclosed are a cyclohexane amine compound and an application thereof for anti-schizophrenia drugs. The cyclohexane amine compound of the present invention has high affinity for a dopamine D3 receptor and 5-ΗΤ1Α, and a lead compound h...  
WO/2014/089480
The present specification provides immunosuppressive Tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodege...  
WO/2014/089209
Engineered multivalent and multispecific binding proteins capable of penetrating the blood-brain barrier (BBB) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.  
WO/2014/088932
Provided herein are methods of treatment of individuals having schizophrenia, or schizophreniform disorder, using angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising...  
WO/2014/086104
The present invention relates to the field of drugs, and more particularly to an AMPK activator and an application thereof in preparing drugs for treating and/or preventing diabetes and/or diabetes complications. The present invention pr...  
WO/2014/087165
The present invention relates to a compound of formula I wherein X is C(R6) or N, Y is C or N, and ring A, ring B, R1 and R2 have the meanings defined herein, provided that when ring B is carbocyclic, X is C(R6); or a pharmaceutically ac...  
WO/2014/087110
A method for the industrial synthesis of an addition salt with a pharmaceutically acceptable acid of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benz amide of formula (I), in which ΗΧ represents a pharmaceutically acceptabl...  
WO/2014/088326
The present invention relates to a composition and health functional food for inhibiting apoptosis of cranial nerve cells, and to a method for inhibiting apoptosis, wherein the composition and health functional food comprising a phosphod...  
WO/2014/089449
Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount o...  
WO/2014/088106
A substance capable of binding to mSin3B, said substance exhibiting an analgesic effect on an ICS (intermittent cold stress) mouse, which is an experimental animal model of fibromyalgia, and, therefore, being useful as a prophylactic or ...  
WO/2014/088519
The present invention relates to certain piperazine-based compounds that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b and/or as ABL or ABL (T315I) inhibitors. The invention further relates to pha...  
WO/2014/086243
Disclosed are a miRNA molecule for negatively regulating a type I interferon pathway and uses thereof, discovering that Has-miR-127-3p is closely related to systemic lupus erythematosus, and also verifying the target pathway of the miRNA...  
WO/2014/085851
The present invention broadly relates to methods for acutely improving/enhancing cognitive performance in a human subject comprising administration of an extract of Bacopa monnieri.  
WO/2014/089149
This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid ...  
WO/2014/087298
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...  
WO/2014/086258
The present invention discloses that Yam glycoprotein can improve the activity of the key enzyme of brain cell mitochondria for oxidative metabolism, i.e., pyruvate dehydrogenase and α-ketoglutarate dehydrogenase, and thus can be used f...  

Matches 101 - 150 out of 46,003